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The Editorial on the research topic
Matricellular Receptors as Potential Targets in Anti-Cancer Therapeutic Strategies
Throughout their life, tumor cells proliferate, migrate, overcome obstacles and survive. All these
actions require multiple interactions between tumor cells and their extracellular surroundings
through specialized cell-surface molecules termed matricellular receptors. We define the
matricellular receptors as being receptors that bind extracellular matrix (ECM) structural proteins
or soluble factors that dynamically act on ECM homeostasis. Matricellular receptors mediate
signalings from the extracellular environment to cell nucleus and drive main biological functions
that are cell growth, survival and migration. Numerous data from the last decade provide
evidence that matricellular receptors are biosensors that allow to a tumor cell to answer to
microenvironmental variations. In this sense they are important contributors to tumor cell
malignancy.
Tumor development is associated with an intense remodeling of ECM that generates biologically
active fragments, termed matricryptins. Ricard-Blum and Vallet review on matricryptins and their
receptor(s) and co-receptor(s), which form a complex network at the surface of tumor and stromal
cells. They describe their roles in angiogenesis, tumor growth and metastasis, and their anti-cancer
drug potential.
Interaction between cells and the ECM largely involves the well-known cell-surface receptors
integrins. Data accumulation during the last 20 years demonstrated that these heterodimeric
proteins act as sensors of cell microenvironment by transducing intracellular signals regulating
cell fate. They are now considered as critical players in cancer progression. Blandin et al.
summarize the current knowledge about integrin involvement in tumor progression and
specifically provide informations about β1 integrins as therapeutic targets to disrupt hallmarks
of cancer.
Beside integrins that bind various ECMmacromolecules, the tyrosine kinase receptors Discoidin
Domain Receptors (DDR) specifically interact with collagens. Collagens, mainly the fibrillar type
I collagen, are major components of the tumor stroma. After summarizing biochemical data on
DDR, Rammal et al. pinpoint the roles of DDR1 and DDR2 in the successive phases of a cancer
development. Finally, the authors review pharmacological approaches to inhibit DDR1 and DDR2,
which might represent valuable targets for anti-cancer therapies.
Elastin is the longest-lived protein in vertebrate and provides elasticity to tissues with high
mechanical constraints such as lung or skin. Its degradation during cancer progression not only
affects its mechanical properties but also generates elastin-derived peptides (EDP) that are actively
involved in the development of cancer. Scandolera et al. describe the role of EDP in tumor
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development and focus their review on the main elastin receptor,
an heterotrimer named the Elastin Receptor Complex (ERC),
unique by its composition and operating mechanism. They
propose anti-ERC therapeutic strategies and describe ERC
involvement in cancer-associated processes such as diabetes and
thrombosis.
Syndecans are transmembrane proteoglycans expressed at the
cell-surface of various cell types. Syndecans are now considered
as key regulators of tumorigenesis and cancer progression,
especially as being involved in the control of cell proliferation,
migration and angiogenesis and in cell-matrix interaction and
dynamics. In this regard, the review by Cheng et al. discusses
the current state of knowledge of syndecans expression and
implication in the field of cancer, with a special and exciting focus
on syndecans binding with PDZ domain-containing proteins.
The regulation of PDZ binding by phosphorylation of the
syndecan cytoplasmic tail is notably debated. Consistently, the
experimental data reported by Kashyap et al. focus on syntenin,
a scaffold protein containing two PDZ domains and known as
an intracellular adaptor for syndecans. To evaluate the potential
benefit of anti-syntenin strategies, the authors report the effects
of syntenin depletion on various cancer cells from distinct
origins. Their results show that syntenin loss of function leads
to a significant decrease in tumor cell proliferation, growth and
migration in each cancer cell model with a noteworthy defect
in the cell-surface expression of active β1-integrin. The authors
conclude that syntenin may constitute a molecular target of
pharmacological interest in the tumor context.
Growth factors receptors are recognized as critical players in
tumor progression by regulating diverse biological activities such
as proliferation, migration or survival through their binding on
Tyrosine Kinase Receptors (TKR). Among this large family, Erb
receptors are often overexpressed, amplified, or mutated in many
forms of cancer, making them important therapeutic targets.
In their review, Appert-Collin et al. describe the regulation of
Erb activity and their role in epithelial-mesenchymal transition.
They illustrate the dedicated therapeutic strategies allowing
their inhibition with an interesting focus on peptides which
mimick transmembrane domains. Beside their role in cancer
progression, TKR are involved in the development of various
fibrotic diseases. In this regard, these diseases also benefit
from advances in the pharmacological strategies developed to
fight cancer. Particularly, VEGFR, PDGFR, FGFR, and EGFR
kinases appear as potential targets for anti-liver fibrosis therapies.
Qu et al. summarize the anti-liver fibrosis effects of multitargeted
TK inhibitors and molecular mechanisms. with a specific focus
on anti-cancer drugs such as sorafenib and erlotinib.
The urokinase receptor (uPAR) is a key cell-surface receptor
generating pericellular proteolysis involved in tissue remodeling
processes and triggering intracellular signaling pathways to
support various cancer-related events. The mini review by
Gonias and Hu gives a synthetic overview of uPAR expression
and function in cancer and provides a relevant schematic
representation of uPAR-related mechanisms at bothsides of the
cell membrane. The authors also address the role of uPAR in the
tumor cell resistance to anti-cancer drugs. This part is quite new
and attractive and constitutes an exciting area to explore for the
future.
While numerousmatricellular receptors only exhibit signaling
properties, the low-density lipoprotein receptor-related protein-1
(LRP-1) further has endocytic capacities. Van Gool et al. provide
an overview of this complex receptor, with a particular focus
on the multiple roles played by LRP-1 in cancer progression.
Furthermore, the authors present recent (pre)clinical data
that suggest applications of LRP-1 as therapeutic tool (in
brain cancers, for crossing the blood-brain barrier) and
diagnostic/prognostic tool. The amount of LRP-1 at the cell
surface is strictly regulated by a proteolytic process termed
shedding, which is itself controlled, notably by cell cholesterol
level. Dekky et al. present original data that highlight the
importance of cell cholesterol distribution in the modulation
of LRP-1 shedding. Their results suggest an inverse correlation
between intracellular cholesterol concentration and LRP-1
shedding efficiency.
As we have mentioned, these matricellular receptors may
constitute relevant targets to fight against malignant diseases. As
examples, Jeanne et al. focus on the CD47 and CD36 molecules
that function as cell-surface receptors for thrombospondin-1,
a large matricellular glycoprotein highly overexpressed within
tumor stroma where it promotes an aggressive phenotype.
The authors review the various therapeutic options, including
antibody-based approaches, therapeutic gene modulation and
TSP-1-derived peptides and mimetics. Interestingly, the authors
also discuss in detail the more recent and innovative approaches
including combination strategies to improve radiotherapy and
chemotherapy.
Through (mini) reviews and original reports, this Research
Topic highlights matricellular receptors that could represent
valuable targets for the development of original anti-cancer
strategies. We would like to thank all the authors for their
important contribution in these exciting fundamental and
applied research fields. We are also grateful to the reviewers and
editors for their constructive comments that allowed our issue to
reach a high standard quality.
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